About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

New Test Helps Diagnose Intellectual Disability in Children

Scan tracks entire genome from a blood sample
FRIDAY, Jan. 17, 2014 (HealthDay News) -- A new test to help diagnose developmental delays and intellectual disability in children based on genetic abnormalities has been approved by the U.S. Food and Drug Administration.
The Affymetrix CytoScan DX Assay scans the entire genetic code from a blood sample and detects chromosomal variations that can lead to developmental and learning problems in children, the agency said Friday in a news release.
Intellectual disability affects as many as 3 percent of children in the United States, the agency said.
Analysis of 960 blood specimens found the new test was better at detecting chromosomal abnormalities that could lead to intellectual disability than other standard tests, the FDA said.
The new test is produced by Affymetrix Inc., based in Santa Clara, Calif.
More information
Medline Plus has more about intellectual disability (http://www.nlm.nih.gov/medlineplus/ency/article/001523.htm ).
Health Headlines
Action-Packed TV a Threat to Your Waistline?View in a lightbox
Family Meals May Defuse Cyberbullying's Impact, Study SaysView in a lightbox
Health Tip: Help Prevent StrokeView in a lightbox
Health Tip: Take it Easy After Blood DonationView in a lightbox
Preterm or Small Birth Tied to Long-Term Risks to Heart, BrainView in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices